Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Study of rhPTH(1-84) in Hypoparathyroidism (Hungary)
2017-003067-36Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of parathyroid hormone 1-84 in hypoparathyroidism and Congenital hypoparathyroidism, sponsored by Takeda. Primary endpoints: Primary efficacy endpoint and Safety endpoint. Started Apr 2018; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
hypoparathyroidismCongenital hypoparathyroidism
Beyond the preview
Go deeper on 2017-003067-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003067-36.